Cart
sales@molnova.com
Anetumab
CAS No. 1954758-84-9
Anetumab( —— )
Catalog No. M36743 CAS No. 1954758-84-9
Anetumab is a novel fully human anti-mesothelin IgG1 antibody that is a naked antibody to Anetumab ravtansine.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 660 | In Stock |
|
| 10MG | 1036 | In Stock |
|
| 25MG | 1568 | In Stock |
|
| 50MG | 2074 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAnetumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAnetumab is a novel fully human anti-mesothelin IgG1 antibody that is a naked antibody to Anetumab ravtansine.
-
DescriptionAnetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1954758-84-9
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Golfier S, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther. 2014 Jun;13(6):1537-48.?
molnova catalog
related products
-
RDR03785
The MIF Antagonist IV, RDR 03785 controls the biological activity of MIF. This small molecule/inhibitor is primarily used for Cell Structure applications.
-
PACAP (1-38), human,...
PACAP (1-38), a novel neuropeptide isolated from the bovine hypothalamus is more active than vasoactive intestinal peptide (VIP) in stimulating adenylate cyclase (EC50=7 nM). PACAP 1-38 (10-9 M) increased substance P (SP), gastrin releasing peptide (GRP), and VIP release. PACAP 1-38 (10-8 M) inhibited gastrin secretion and stimulated somatostatin secretion and motility dose-dependently.
-
LtaS-IN-1
LtaS-IN-1 is an effective inhibitor of Lipoteichoic acid synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology.
